Open-label trial of imatinib mesylate in patients with refractory desmoplastic small round cell tumors (DSRCT) expressing PDGF-R [platelet derived growth factor receptor].

Trial Profile

Open-label trial of imatinib mesylate in patients with refractory desmoplastic small round cell tumors (DSRCT) expressing PDGF-R [platelet derived growth factor receptor].

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 Apr 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top